Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Recent & Breaking News (NDAQ:NTLA)

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

GlobeNewswire 8 days ago

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire November 7, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 5, 2024

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

GlobeNewswire October 31, 2024

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire October 24, 2024

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

GlobeNewswire October 10, 2024

Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

GlobeNewswire October 7, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 3, 2024

Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions

GlobeNewswire October 1, 2024

Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific Meeting

GlobeNewswire September 12, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire September 3, 2024

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm

Newsfile August 16, 2024

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

GlobeNewswire August 8, 2024

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

GlobeNewswire August 1, 2024

Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

GlobeNewswire July 30, 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire July 24, 2024

Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm

PR Newswire July 2, 2024

Intellia Therapeutics Announces CFO Transition

GlobeNewswire June 26, 2024

Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

GlobeNewswire June 25, 2024

Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

GlobeNewswire June 17, 2024